|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, year** | **Study Design** | **Number of Centers  Country** | **Duration of Followup** | **Interventions** | **Patient Characteristics** | **Inclusion/Exclusion Criteria** | **Randomized Analyzed Attrition** |
| Bressler, 2013126 MARINA (post-hoc analysis) | RCT | Multicenter (96 sites) United States | 2 years | A. Ranibizumab injection 0.5 mg/month (n=240) B. Ranibizumab injection 0.3 mg/month (n=238) C. Sham injection (n=238) | A vs. B vs. C (post-hoc analysis) Proportion of patients responding "yes" to NEI VFQ-25 question "are you currently driving at least once in while?": 68.1% vs. 68.2% vs. 69.6% B vs. C (group A not reported) VA better than 20/40 in one or both eyes: n=110 vs. 133 VA worse than 20/40 in both eyes:  n= 129 vs. 104 | Age ≥50 years with subfoveal CNV secondary to AMD and best corrected VA 20/40 to 20/320 with primary of recurrent CNV secondary to AMD with maximum lesion size 12 disk areas, presumed recent progression | Randomized: 716 Analyzed: 716 Attrition: 0% |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author, year** | **Clinical Health Outcomes** | **Adverse Events** | **Quality** | **Comment** |
| Bressler, 2013126 MARINA (post-hoc analysis) | **A vs. B vs. C (1 year followup)** Proportion of patients responding "yes" to NEI VFQ-25 question "are you currently driving at least once in while?": 65.5% vs. 64.3% vs. 52.1% (n/N not reported); change from baseline -2.6% vs. -3.9% vs. -17.5%; A vs. C p=0.0005; B vs. C p=0.010 Proportion of patients reporting driving at baseline and still driving at followup: 87.8% vs. 87.8% vs. 74.0% (n/N not reported); A vs. C p=0.002; B vs. C p=0.002 Mean change from baseline in NEI VFQ-25 driving function subscale (scale 0-100; higher score = better function): -2.1 vs. -0.4 vs. -12.5; A vs. C p=0.0004, mean treatment difference 12.1 (95% CI 7.1 to 17.1); B vs. C p<0.001, mean treatment difference 10.4 (95% CI 5.2 to 15.7) **A vs. B vs. C (2 year followup)** Proportion of patients responding "yes" to NEI VFQ-25 question "are you currently driving at least once in while?": 60.4% vs. 57.5% vs. 49.2% (n/N not reported); change from baseline -7.7% vs. -10.7% vs. -20.4%; A vs. C p=0.026; B vs. C p=0.010 Proportion of patients reporting driving at baseline and still driving at followup (n/N not reported): 81.3% vs. 78.4% vs. 67.2%; A vs. C p=0.008; B vs. C p=0.090 Mean change from baseline in NEI VFQ-25 driving function subscale: -2.1 vs. -2.8 vs. -17.3; A vs. C p<0.001, mean treatment difference 14.5 (95% CI 8.9 to 20.1); B vs. C p<0.001, mean treatment difference 15.2 (95% CI 9.4 to 21.0) **A vs. C (1 year followup; results for group B not reported)** Proportion of patients with VA better than 20/40 in one or both eyes at baseline and at followup: 82.7% (91/110) vs. 62.4% (83/133); RR 1.33 (95% CI 1.13 to 1.55) Proportion of patients with VA worse than 20/40 in both eyes at baseline improved to VA better than 20/40 in one or both eyes at followup: 27.9% (36/129) vs 10.6% (11/104); RR 2.64 (95% CI 1.41 to 4.92) **A vs. C (2 year followup; results for group B not reported)** Proportion of patients with VA better than 20/40 in one or both eyes at baseline and at followup: 77.2% (85/110) vs. 56.4% (75/133); RR 1.37 (95% CI 1.14 to 1.64) Proportion of patients with VA worse than 20/40 in both eyes at baseline improved to VA better than 20/40 in one or both eyes at followup: 31.9% (41/129) vs. 7.7% (8/104); RR 4.13 (95% CI 2.03 to 8.42) | A vs B CVA: 3.3% (8/239) vs. 1.3% (3/236); RR 2.63 (95% CI 0.71 to 9.81)  B vs. C CVA: 1.3% (3/238) vs. 1.3% (3/326); RR 0.99 (95% CI 0.20 to 4.86) | Good | ANCHOR results outside the scope of this report (ranibizumab vs. verteporfin) |

**Abbreviations:** AMD = age-related macular degeneration; CI = confidence interval, CNV = choroidal neovascularization; CVA = cerebrovascular accident; MI = myocardial infarction, NEI VFQ-25 = National Eye Institute Visual Function Questionairre 25, RCT = randmized controlled trial, RR = risk ratio, VA = visual acuity.

**Note:** Prior report studies abstracted in Appendix B.